November 14, 2012 — Vital Images received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for 3-D viewing through its universal viewer, VitreaView. The company also released tablet viewing capabilities for VitreaView.
Introduced in June of 2011, VitreaView provides a consistent image viewing experience across the patient continuum of care. VitreaView is used as a communication tool for DICOM (digital imaging and communications in medicine) and non-DICOM medical images through a standardized viewer, giving clinicians access to these images through a variety of systems, including EMR (electronic medical record), EHR (electronic health record) or HIE (health information exchange).
“Delivering high quality products is fundamentally important to Vital; seeking FDA clearance is just a part of our standard process,” said Erkan Akyuz, president and CEO at Vital Images Inc. “It is critical that our customers have confidence in the tools they depend on for delivering care. Now with 3-D and tablet capabilities available via VitreaView, our customers, particularly referring physicians and clinicians, have more functionality and easier access to the tools they need. Also, with access to images through the EMR as part of the Stage 2 meaningful use criteria, VitreaView integrated with a certified EMR enables the ability to meet this objective, with a toolset and infrastructure that also meets the needs of clinical users and IT administrators.”
VitreaView enables flexible deployment options, including leveraging virtualized environments and allowing access to multiple databases, thus providing a universal imaging layer at the enterprise level. VitreaView is also designed to eliminate the need to integrate disparate image viewing portals by providing a single, standardized imaging layer for referring clinicians. This allows administrators to move away from managing disparate departmental imaging solutions and provide access through a consolidated universal viewer.
For more information: www.vitalimages.com
February 01, 2024 
